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Intravenous thyrotrophin releasing hormone (TRH) caused a 6.5~fold increase in plasma prolactin (PRL) 
in rats carrying implanted pituitary tumours. Vasoactive intestinal polypeptide (VIP) had no effect, but 
TRH given after VIP raised TRH stimulated secretion 13-fold above basal. 31P NMR spectroscopy showed 
that VIP caused a decrease in high energy metabolites (depleted phosphocreatine, levated inorganic phos- 
phate and lowered intracellular pH). TRH alone caused a similar but smaller effect; given after VIP, it 
caused no detectable depletion. We suggest hat the changes in high energy metabolite cencentrations reflect 
increased cellular energy consumption consistent with a priming process (stage 1) in PRL secretion, followed 
by hormone release (stage 2). VIP induces stage 1 whereas RTH induced both stages. 
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1. INTRODUCTION 
Stimulation of PRL secretion is less well under- 
stood than inhibition. TRH is known to increase 
secretion but it is likely that other factors also take 
part. Several authors have reported that VIP can 
increase PRL secretion [l-3], and VIP is present in 
high concentrations in the hypothalamus [4] and in 
pituitary portal blood of rats [5]. However, the ef- 
fect of VIP varies with the experimental method 
used and there are conflicting views as to its impor- 
tance. 
titularly useful in studying highly labile phosphate 
compounds which may be degraded by conven- 
tional freeze-clamping and extraction but can be 
measured non-invasively by 31P NMR. 
Recent developments in nuclear magnetic 
resonance (NMR) spectroscopy using surface coil 
methods [6-B] have permitted investigation of 
metabolic changes in whole organs. This is par- 
We have previously shown [9] that PRL-secret- 
ing tumours arising spontaneously in rats provide 
a very good experimental model for studying the 
hormonal control mechanisms of human prolac- 
tinomas; they continue to function even when 
transplanted to subcutaneous sites. We have 
therefore applied 31P NMR spectroscopy to these 
tumours in the living animal to study the in- 
tracellular metabolic changes accompanying 
stimulation of PRL secretion by TRH and VIP. 
2. MATERIALS AND METHODS 
Abbreviations: TRH, thyrotrophin releasing hormone; 2.1. Hormone experiments 
PRL, prolactin; VIP, vasoactive intestinal polypeptide; Tissue originating from spontaneously arising 
PCR, phosphocreatine; Pi, inorganic phosphate PRL-secreting rat pituitary tumours was trans- 
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planted subcutaneously into the flanks of young 
female Wistar rats as in [9]. When the resulting 
tumours were greater than 2 cm in diameter the 
animals were treated daily with 5 ,ug subcutaneous 
oestradiol benzoate for 3 days. On the fourth day 
they were anaesthetised with urethane (0.114 g/kg) 
and the external jugular vein was catheterised. 
After equilibration for 1 h, 3-5 blood samples were 
taken at intervals of 10 min. Rats were then given, 
as a bolus i.v. injection, either 8 fig/100 g VIP or 
0.8 /cg/lOO g TRH at the times shown in fig.1. 
PRL was measured using the protocol and 
materials supplied by NIADDK (Bethesda, MD). 
bearing rats was followed by the well recognized 
increase in plasma prolactin concentrations, up to 
6.5fold above the basal values of 419+ 127 (SE) 
ng/ml (fig.1). In these tumours a single intraven- 
ous injection of VIP alone had no significant effect 
on prolactin secretion, but if TRH was given 40 
min after VIP, prolactin secretion rose up to 
13-fold above basal values (fig.1). In similar ex- 
periments with normal rats in which basal prolac- 
tin concentrations were 14.8k2.7 ng/ml, VIP 
given in the same dosage produced a slight but 
non-significant effect on prolactin secretion, and 
after the subsequent injection of TRH the mean 
plasma hormone value was 32.4 * 2.5 ng/ml. 
2.2. NMR 
After 3 days oestradiol treatment, rats bearing 
transplanted PRL-secreting tumours were anaes- 
thetised and their jugular veins catheterised. A 
2-turn, 2 cm diameter radiofrequency coil was 
placed on the skin over the tumour and the animal 
was placed within the bore (27 cm) of an Oxford 
Research Systems TMR-32 spectrometer. The sur- 
face coil had an external standard consisting of a 
capillary containing methylene diphosphonate 
mounted in its plane. 
3.2. Effect of VIP and TRH on 3’P NA4R spectra 
Typical NMR spectra obtained from a prolactin- 
secreting tumour without treatment, after the ad- 
ministration of VIP alone, and after TRH alone 
are shown in fig.2. In the control, untreated, 
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Experiments were performed using a sweep 
width of 2 kHz, 15 ,us radiofrequency pulses and a 
2 s recycle time. Studies with phantoms showed 
that these conditions gave signals almost entirely 
from the tumour and not from skin or underlying 
muscle. Control experiments with longer recycle 
times showed that signals were not lost by satura- 
tion. 
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The resonances were integrated by the routine 
supplied with the spectrometer after deconvolution 
to remove underlying broad components. Control 
experiments in which peaks were cut out from 
spectra and weighed, showed that deconvolution 
did not significantly alter relative peak integrals. 
The interspectral coefficient of variation of the in- 
tegrals of the peaks of the methylene diphosphon- 
ate external standard was 6.3%. Intracellular pH 
was measured from the chemical shift of the Pi 
resonance [8]. 
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3. RESULTS 
3.1. Effects of VIP and TRH on prolactin 
secretion 
Fig. 1. Effect of VIP and TRH on plasma prolactin con- 
centrations in rats with transplanted prolactin-secreting 
pituitary tumours. Values are expressed as percentages 
of basal hormone secretion f SE. Order of peptides 
given was: (H) VIP followed by TRH (n = 5); 
The intravenous injection of TRH to tumour (IS-O) TRH followed by VIP (n = 5). 
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Fig.2. NMR spectra from a transplanted prolactin- 
secreting pituitary tumour in the living rat. CON, un- 
treated; VIP, 4 min after injection; TRH, 4 min after in- 
jection. (0) Methylene diphosphonic acid added as exter- 
nal standard, (1) phosphomonoesters, (2) inorganic 
phosphate, (3) phosphodiesters, (4) phosphocreatine, (5) 
yATP + PATP, (6) aATP + ADP, (7) ,&ATP. 
tumour spectrum, 7 peaks were present comprising 
the a-phosphate of ATP (together with some NAD 
and ADP), the &phosphate of ATP, the y- 
phosphate of ATP (with some ADP), PCr, phos- 
phodiesters, Pi and phosphomonoesters. Treat- 
ment with VIP produced a considerable increase in 
the Pi peak and a reduction in the PCr peak. These 
changes occurred within 4 min of giving the pep- 
tide and usually returned to the resting level after 
about 24 min. Changes observed after giving TRH 
were much smaller. 
Fig.3 shows the mean quantitative effects after 
injections of VIP or TRH on the Pi content in 11 
tumours. Both peptides increased Pi but the in- 
crease produced by VIP (60% above basal values) 
was significantly greater (pcO.05) than that pro- 
duced by TRH (25% above basal values). In addi- 
tion, VIP caused a significant fall in the intra- 
cellular pH of the tumours from 7.05 kO.06 to 
6.7 + 0.1 (p<O.OS) which was not seen after TRH. 
The effect of TRH administered after VIP is 
shown in the right hand portion of fig.3. There 
were no significant changes in Pi or intracellular 
pH. On the other hand, when VIP was given after 
TRH it still induced a rise in Pi and a fall in the in- 
tracellular pH (not shown). 
3.3. Vasodilation by VIP 
It is well recognized that VIP has very potent 
vasodilator properties and to exclude the possibili- 
ty that changes in blood flow could affect the 
NMR spectra, control experiments were carried 
out with intravenous injections of another power- 
ful vasodilator drug, sodium nitroprusside in doses 
sufficient to produce a similar fall in blood pres- 
sure. No alterations in the NMR spectra were 
observed. 
4. DISCUSSION 
Although many peptides can increase plasma, 
PRL concentrations after intravenous injection 
most probably act by affecting the release of 
dopamine from the hypothalamus. Testing the 
direct action of putative PRL releasing hormones 
on the cells of the pituitary usually requires in vitro 
techniques. These often produce conflicting rep- 
orts: some authors have found that VIP stimulates 
PRL secretion in vitro [2,3,10,1 l] while others 
have not, or have only obtained some reversal of 
dopamine inhibition [ 1,121. 
The data in fig. 1 show that VIP enhances TRH- 
induced PRL secretion from tumour cells without 
itself causing significant hormone release. The 
metabolic changes accompanying these effects 
were visualised by NMR using a surface coil placed 
over the tumour which monitored changes in high 
energy phosphate compounds and in intracellular 
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Fig.3. Quantitative changes in (A) intracellular pH and (B) inorganic phosphate of prolactin-secreting tumours follow- 
ing injections of VIP and/or TRH. Pi changes are given as percent change of control spectra *SE. (O--U) VIP, 
(M) TRH, (M ) TRH after VIP (the gap in the time scale between giving VIP and subsequently TRH varied 
between 4 and 20 min). 
pH (fig.2). Both TRH and VIP caused depletion of 
PCr and a rise in Pi; VIP also caused a fall in in- 
tracellular pH. The most likely explanation for 
these changes is that cellular energy stores (of 
which PCr is the most immediately accessible) were 
being depleted by some energy requiring process. 
An alternative explanation would be that tumour 
blood flow was reduced by the hormone and that 
this ischaemia (or some other VIP-induced impair- 
ment of energy conversion) caused the depletion of 
cellular energy reserves. VIP, as its name implies, 
is vasoactive, but control experiments using the 
powerful vasodilator sodium nitroprusside failed 
to alter the NMR spectrum, suggesting that the 
VIP effect was not caused by a central vasodilator 
action. This does not rule out a local action of VIP 
or the release of compensatory vasoconstrictor 
elements induced by VIP but these explanations 
would not account for the similar metabolic effects 
induced by TRH which is not thought to have 
vasoactive properties. The results suggest hat PRL 
secretion is a two-stage process. The first step 
(stage 1) depletes the cell’s energy reserves but does 
not necessarily result in PRL release, whereas tage 
2, release of PRL into the blood stream, has a 
negligible energy requirement. VIP induces stage 1 
but not stage 2. TRH induces both stages but in- 
duces stage 1 less effectively than VIP at the ap- 
proximately equimolar doses used. Tumours 
pretreated with VIP show no stage 1 response 
when subsequently treated with TRH, even though 
PRL secretion is enhanced, whereas a stage 1 
response can be induced by VIP in TRH-treated 
tumours. 
The second messengers involved in the actions of 
TRH and VIP have been extensively investigated. 
In recent years it has become clear that, although 
TRH-induced changes in CAMP have been measur- 
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ed by many authors, a change in CAMP is not 
essential for the acute TRH stimulation of PRL 
release. The second message is now thought to be 
a rise in intracellular Ca’+ (review [ 131). The action 
of VIP in various tissues, however, seems always 
to be mediated by CAMP [14]. 
This paper provides evidence from a combina- 
tion of hormonal and NMR investigations that on- 
ly stage 1 of PRL release is influenced by VIP, 
presumably acting through CAMP. Hormone 
release, stage 2, is stimulated by TRH which can 
also, but does not invariably, induce stage 1. Since 
it is thought that TRH induces PRL release (i.e., 
stage 2) via a Ca2+ -mediated mechanism, its action 
in inducing stage 1 corresponds to the CAMP 
changes which are sometimes seen following the 
action of TRH. For example, in serum-containing 
medium, TRH stimulates PRL release from GH3 
cells without altering CAMP, a pure stage 2 effect. 
In serum-free medium, on the other hand, TRH in- 
duces both PRL release and CAMP formation, i.e., 
both stages 1 and 2 [15]. A plausible hypothesis is 
that stage 1 involves an energy requiring prepara- 
tion of the cell for hormone release, whereas the 
release of hormone in stage 2 (presumably mediat- 
ed by a Ca*+ -induced membrane depolarisation) 
requires relatively little energy. VIP brings more of 
the hormone store of tumour cells into readiness 
for secretion so that subsequent TRH treatment 
causes a massive hormone release with little de- 
mand on cellular energy reserves. 
These initial studies would appear to be the first 
demonstration of NMR spectral changes accompa- 
nying stimulation of an endocrine tumour, and the 
technique promises to be useful in explaining fur- 
ther intracellular events which underlie hormone 
secretion. 
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